Orgabio: A niche beverage manufacturer that is starting to show stronger scale, improving margins, and clearer earnings traction

Orgabio Holdings Berhad may still be relatively underfollowed by the market, but from a fundamental perspective, the company is beginning to look more interesting as its operating numbers improve and its newer capacity starts to contribute more meaningfully. At its core, Orgabio is involved in the manufacturing of instant beverage premix products, supplying third-party brand owners through formulation, blending, and related manufacturing services. In simple terms, this is a consumer-products business, but one that sits behind the brands rather than competing mainly at the retail shelf level. That business model matters because it gives Orgabio exposure to rising demand for convenient, functional, and ready-to-mix beverages without having to rely only on building a single flagship consumer brand itself.

The latest available quarterly result already shows that the business is moving in the right direction. For the quarter ended 31 December 2025, Orgabio reported RM40.73 million in revenue, up from RM25.40 million a year earlier. Profit before tax rose to RM3.91 million from RM1.86 million, while net profit increased to RM2.81 million from RM1.27 million. On a six-month basis, revenue climbed to RM79.79 million from RM48.84 million, and net profit more than doubled to RM5.54 million from RM2.34 million. Basic EPS for the six months improved to 2.23 sen from 0.94 sen, while net assets per share rose to 26 sen from 24 sen.

That kind of growth is not just cosmetic. The improvement appears to be supported by real operating momentum. NST’s coverage of the result said the quarter was lifted by stronger gross profit margins, while the revenue increase was driven by higher demand for instant beverage premix manufacturing services, especially in the domestic market, with overseas sales also continuing to expand. This is important because it suggests Orgabio’s earnings growth is not only coming from higher sales volume, but also from better profitability at the gross level.

One of the more interesting angles here is that Orgabio seems to be entering a stronger utilisation phase. A January 2026 interview with China Press revealed that the company’s new Industry 4.0 factory was then operating at only around 30% capacity, yet had already helped drive a sharp earnings improvement. If that remains broadly true, it implies that Orgabio may still have room to grow output and revenue without needing immediate major capacity expansion again. For investors, that kind of operating leverage can matter a lot, because it means future sales growth could potentially flow through to earnings more efficiently.

The balance-sheet side also looks healthy enough to support growth. As of the latest reported quarter, Orgabio’s net assets per share improved to RM0.26 from RM0.24, reflecting profit retention and a stronger equity base. While the market often focuses first on quarterly earnings, the steady increase in net assets is another useful signal that the company is building value rather than simply producing short bursts of revenue.

From a business-model perspective, Orgabio’s positioning also makes sense in the current consumer environment. Demand for convenient beverages, functional drinks, and contract-manufactured consumer products remains structurally relevant, especially as more brand owners choose to outsource formulation and production rather than build their own manufacturing capability from scratch. This gives specialised manufacturers like Orgabio a potentially attractive niche: they can benefit from broader end-market demand while serving multiple customers instead of depending on a single retail brand. That does not eliminate competition, but it does provide a more diversified demand base than a one-brand consumer company would typically have.

What investors should still watch, of course, is whether the recent growth can be sustained. Contract manufacturing businesses can be sensitive to customer order concentration, raw material costs, and margin swings if utilisation weakens. But for now, the latest numbers do not point to a company under pressure. Instead, they show a business that is scaling up, improving profitability, and seemingly benefiting from both stronger demand and better plant efficiency.

Overall, Orgabio now looks more like a company moving into a stronger earnings phase rather than just a quiet ACE name waiting for attention. The latest quarter showed meaningful revenue and profit growth, gross margins improved, and the business still appears to have capacity headroom for further expansion. For investors who like consumer-related companies with a manufacturing edge and improving financial momentum, Orgabio may be one of the more interesting underfollowed names to keep on the radar.